2021 STI Treatment Guidelines
The 2021 STI Treatment Guidelines is a deleted CDC publication, presented here in its unchanged original form. This document provides clinical guidance for healthcare providers on the diagnosis and treatment of sexually transmitted infections (STIs), including recommended and alternative medication regimens.
Key Features of the Guide:
Disease-Specific Treatment Recommendations: Includes guidelines for the management of bacterial vaginosis, chlamydia, gonorrhea, syphilis, trichomoniasis, genital herpes, HPV, pelvic inflammatory disease (PID), and more.
Recommended & Alternative Regimens: Covers first-line therapies alongside alternative treatments for patients with contraindications or drug allergies.
Special Populations: Provides treatment protocols for pregnant individuals, neonates, children, and people with HIV.
Partner Management: Stresses the importance of partner notification and treatment to prevent reinfection and reduce STI transmission.
Antibiotic Resistance Considerations: Addresses emerging drug resistance and provides guidance on adjusting treatment based on susceptibility testing.
Route of Administration & Dosage: Outlines oral, intramuscular (IM), and intravenous (IV) options depending on the severity of infection.
Disclosure:
This document remains unaltered from its original CDC version before its deletion. It is intended as a clinical reference for healthcare providers, public health officials, and researchers managing sexually transmitted infections in diverse patient populations.
The 2021 STI Treatment Guidelines is a deleted CDC publication, presented here in its unchanged original form. This document provides clinical guidance for healthcare providers on the diagnosis and treatment of sexually transmitted infections (STIs), including recommended and alternative medication regimens.
Key Features of the Guide:
Disease-Specific Treatment Recommendations: Includes guidelines for the management of bacterial vaginosis, chlamydia, gonorrhea, syphilis, trichomoniasis, genital herpes, HPV, pelvic inflammatory disease (PID), and more.
Recommended & Alternative Regimens: Covers first-line therapies alongside alternative treatments for patients with contraindications or drug allergies.
Special Populations: Provides treatment protocols for pregnant individuals, neonates, children, and people with HIV.
Partner Management: Stresses the importance of partner notification and treatment to prevent reinfection and reduce STI transmission.
Antibiotic Resistance Considerations: Addresses emerging drug resistance and provides guidance on adjusting treatment based on susceptibility testing.
Route of Administration & Dosage: Outlines oral, intramuscular (IM), and intravenous (IV) options depending on the severity of infection.
Disclosure:
This document remains unaltered from its original CDC version before its deletion. It is intended as a clinical reference for healthcare providers, public health officials, and researchers managing sexually transmitted infections in diverse patient populations.
The 2021 STI Treatment Guidelines is a deleted CDC publication, presented here in its unchanged original form. This document provides clinical guidance for healthcare providers on the diagnosis and treatment of sexually transmitted infections (STIs), including recommended and alternative medication regimens.
Key Features of the Guide:
Disease-Specific Treatment Recommendations: Includes guidelines for the management of bacterial vaginosis, chlamydia, gonorrhea, syphilis, trichomoniasis, genital herpes, HPV, pelvic inflammatory disease (PID), and more.
Recommended & Alternative Regimens: Covers first-line therapies alongside alternative treatments for patients with contraindications or drug allergies.
Special Populations: Provides treatment protocols for pregnant individuals, neonates, children, and people with HIV.
Partner Management: Stresses the importance of partner notification and treatment to prevent reinfection and reduce STI transmission.
Antibiotic Resistance Considerations: Addresses emerging drug resistance and provides guidance on adjusting treatment based on susceptibility testing.
Route of Administration & Dosage: Outlines oral, intramuscular (IM), and intravenous (IV) options depending on the severity of infection.
Disclosure:
This document remains unaltered from its original CDC version before its deletion. It is intended as a clinical reference for healthcare providers, public health officials, and researchers managing sexually transmitted infections in diverse patient populations.